These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20364358)

  • 1. Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis.
    Emad Y; Shehata M; Ragab Y; Saad A; Hamza H; Abou-Zeid A
    Mod Rheumatol; 2010 Aug; 20(4):358-65. PubMed ID: 20364358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.
    Shovman O; Gilburd B; Zandman-Goddard G; Sherer Y; Orbach H; Gerli R; Shoenfeld Y
    Clin Dev Immunol; 2005 Sep; 12(3):197-202. PubMed ID: 16295525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
    Berglin E; Johansson T; Sundin U; Jidell E; Wadell G; Hallmans G; Rantapää-Dahlqvist S
    Ann Rheum Dis; 2006 Apr; 65(4):453-8. PubMed ID: 16176994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
    Chang PY; Yang CT; Cheng CH; Yu KH
    Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?
    Girelli F; Foschi FG; Bedeschi E; Calderoni V; Stefanini GF; Martinelli MG
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):127-30. PubMed ID: 15180353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in Iranian patients with rheumatoid arthritis: evaluation of clinical value and association with disease activity.
    Shakiba Y; Koopah S; Jamshidi AR; Amirzargar AA; Massoud A; Kiani A; Nicknam MH; Nazari B; Nikbin B
    Iran J Allergy Asthma Immunol; 2014 Jun; 13(3):147-56. PubMed ID: 24659118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).
    Forslind K; Ahlmén M; Eberhardt K; Hafström I; Svensson B;
    Ann Rheum Dis; 2004 Sep; 63(9):1090-5. PubMed ID: 15308518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus.
    Popescu C; Zofotă S; Bojincă V; Ionescu R
    Rom J Intern Med; 2013; 51(3-4):179-87. PubMed ID: 24620631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis.
    Krol A; Garred P; Heegaard NH; Christensen AF; Hetland ML; Stengaard-Pedersen K; Junker P; Madsen HO; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Pedersen JK; Svendsen AJ; Tarp U; Pødenphant J; Lindegaard H; Østergaard M; Hørslev-Petersen K; Jacobsen S
    Scand J Rheumatol; 2015; 44(1):8-12. PubMed ID: 25205362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis.
    Lee DM; Phillips R; Hagan EM; Chibnik LB; Costenbader KH; Schur PH
    Ann Rheum Dis; 2009 Feb; 68(2):201-8. PubMed ID: 18390910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
    Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
    Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis.
    Shen R; Ren X; Jing R; Shen X; Chen J; Ju S; Yang C
    Lab Med; 2015; 46(3):226-9. PubMed ID: 26199263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cyclic citrullinated peptide antibodies in patients with sarcoidosis.
    Kobak S; Ylmaz H; Sever F; Duran A; Sen N
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):206-10. PubMed ID: 25363220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
    Us D; Gülmez D; Hasçelik G
    Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor.
    Yamane T; Hashiramoto A; Tanaka Y; Tsumiyama K; Miura Y; Shiozawa K; Chihara K; Shiozawa S
    J Rheumatol; 2008 Mar; 35(3):414-20. PubMed ID: 18203327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.